# Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT

> **NCT03733340** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 250 (estimated)

## Conditions studied

- Antibacterial Prophylaxis
- Hematological Malignancies
- Allogenetic Hematopoietic Stem Cell Transplantation
- Imipenem

## Interventions

- **DRUG:** Imipenem

## Key facts

- **NCT ID:** NCT03733340
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733340, "Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03733340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*